Caribou Biosciences, Inc. (NASDAQ:CRBU) is included in our list of the 7 most volatile stocks under $5 for day trading.
A dose bottle of the medication is in the medical tech’s hand
On February 2, 2026, Clear Street began covering Caribou Biosciences, Inc. (NASDAQ:CRBU) with a ‘Buy’ rating and a $13 price target. The firm’s bullish stance was attributed to the company’s off-the-shelf allogeneic CAR-T program, which was described as the primary value generator. The investment bank projected 2040 peak sales of $992 million with a 30% chance of success for the lead candidate, vispa-cel. Caribou is preparing to begin a registrational Phase 3 trial in second-line or later large B-cell lymphoma. Additionally, with a 20% chance of success, Clear Street forecasts that CB-011 may reach $734 million in peak 2040 sales, highlighting both clinical risk and upside potential.
On January 6, 2026, BofA cited a wider reset in U.S. biopharma valuations, cutting its price target on Caribou Biosciences, Inc. (NASDAQ:CRBU) from $8 to $6 while keeping a ‘Buy’ rating. Although durability remains the main point of contention for investors, the investment firm argued that better access to capital, M&A activity, and encouraging data catalysts indicate a biotech turnaround.
Caribou Biosciences, Inc. (NASDAQ:CRBU) focuses on advancing an internal oncology pipeline and supporting broader therapeutic and biotech research uses by leveraging CRISPR genome-editing technology to develop off-the-shelf CAR-T and CAR-NK cell treatments.
While we acknowledge the potential of CRBU as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: What Are the Best Stocks to Buy Right Now? and 10 Stocks Under $1 That Will Explode.
Disclosure: None.
